Drug Trial Radar · NCT06334315
Oral Contraceptive Pill (OCP) Pharmacogenomics
Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
700
Planned (sponsor's estimate)
Start
Oct 29, 2024
Primary completion
May 2028
Study completion May 2028
Sponsor
- Lead sponsor
- Yale UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- First posted
- Mar 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate how differences in specific parts of our DNA can influence how individual bodies break down the hormones contained within oral contraceptive pills, which could affect how well these birth control pills work to prevent pregnancy. The investigators are also interested in exploring how these differences in our DNA can also explain why patients taking the exact same formulation of birth control pill will experience very different side effects. The main questions it aims to answer are: * Do individuals with the CYP3A7\*1C variant have increased metabolism of both desogestrel and ethinyl estradiol when taking a combined oral contraceptive pill? * Do individuals with the CYP3A7\*1C variant experience higher rates of breakthrough ovulation while taking a desogestrel/ethinyl estradiol combined oral contraceptive pill? * What novel genetic loci are associated with alterations in steroid hormone pharmacokinetics and pharmacodynamics among a larger cohort of combined oral contraceptive pill users? Participants will take a specific formulation of combined oral contraceptive pill (desogestrel/ethinyl estradiol) and undergo the following procedures: * Blood draw to measure the amount of progestin and estrogen in their system from the combined oral contraceptive pill * Questionnaires to assess side effects possibly caused by the combined oral contraceptive pill * Blood draw to measure endogenous hormone levels and biomarkers that may be affected by the combined oral contraceptive pill * A transvaginal ultrasound to measure any ovarian follicles (optional procedure)
Conditions
- Contraception
- Pharmacogenomic Drug Interaction
Interventions
Desogestrel / Ethinyl Estradiol PillDrug
Standard pill packs containing 21 active pills and 7 placebo pills
Primary outcomes
What the sponsor says the trial is designed to measure.
- Serum etonogestrel concentrationTime frame: Measured as a trough concentration on Cycle 1, Day 22 (each cycle is 28 days)
- Serum ethinyl estradiol concentrationTime frame: Measured as a trough concentration on Cycle 1, Day 22 (each cycle is 28 days)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of Colorado Anschutz Medical Campus
Aurora, Colorado · Recruiting
Yale University
New Haven, Connecticut · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.